Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 52


Long term outcome and side effects in patients receiving low-dose I125 brachytherapy: a retrospective analysis.

Logghe P, Verlinde R, Bouttens F, Van den Broecke C, Deman N, Verboven K, Maes D, Merckx L.

Int Braz J Urol. 2016 Sep-Oct;42(5):906-917. doi: 10.1590/S1677-5538.IBJU.2015.0542.


Role of hormonal therapy for prostate cancer: perspective from Japanese experiences.

Namiki M, Ueno S, Kitagawa Y.

Transl Androl Urol. 2012 Sep;1(3):160-72. doi: 10.3978/j.issn.2223-4683.2012.07.03. Review.


Evaluation of the utilization of external radiotherapy in the treatment of localized prostate cancer in Andalusia, Spain.

Expósito J, Linares I, Castillo I, Martínez M, Vargas P, Herruzo I, Medina JA, Palacios A, Bayo E, Peracaula F, Jaén J, Sánchez JA, Ortiz MJ.

Radiat Oncol. 2015 Dec 30;10:265. doi: 10.1186/s13014-015-0572-8.


International prostate symptom score (IPSS) change and changing factor in intensity-modulated radiotherapy combined with androgen deprivation therapy for prostate cancer.

Tomita N, Oze I, Shimizu H, Yoshida M, Kimura K, Takehana K, Shimizu A, Makita C, Tachibana H, Kodaira T, Soga N, Ogura Y, Hayashi N.

Nagoya J Med Sci. 2015 Nov;77(4):637-46.


Seed migration after transperineal interstitial prostate brachytherapy by using loose seeds: Japanese prostate cancer outcome study of permanent iodine-125 seed implantation (J-POPS) multi-institutional cohort study.

Nakano M, Yorozu A, Saito S, Sugawara A, Maruo S, Kojima S, Kikuchi T, Fukushima M, Dokiya T, Yamanaka H.

Radiat Oncol. 2015 Nov 14;10:228. doi: 10.1186/s13014-015-0532-3.


125I Seed Implant Brachytherapy for Painful Bone Metastases After Failure of External Beam Radiation Therapy.

Feng S, Wang L, Xiao Z, Maharjan R, Chuanxing L, Fujun Z, Jinhua H, Peihong W.

Medicine (Baltimore). 2015 Aug;94(31):e1253. doi: 10.1097/MD.0000000000001253.


A novel perineal shield for low-dose-rate prostate brachytherapy.

Weiner JP, Schwartz D, Safdieh J, Polubarov A, Telivala T, Worth M, Schreiber D.

J Contemp Brachytherapy. 2015 Jun;7(3):197-202. doi: 10.5114/jcb.2015.52071. Epub 2015 Jun 8.


Review of advanced catheter technologies in radiation oncology brachytherapy procedures.

Zhou J, Zamdborg L, Sebastian E.

Cancer Manag Res. 2015 Jul 16;7:199-211. doi: 10.2147/CMAR.S46042. eCollection 2015. Review.


Impact of post-implant dosimetric parameters on the quality of life of patients treated with low-dose rate brachytherapy for localised prostate cancer: results of a single-institution study.

Veccia A, Caffo O, Fellin G, Mussari S, Ziglio F, Maines F, Tomio L, Galligioni E.

Radiat Oncol. 2015 Jun 10;10:130. doi: 10.1186/s13014-015-0434-4.


Analysis of monotherapy prostate brachytherapy in patients with prostate cancer. Initial PSA and Gleason are important for recurrence?

Galego P, Silva FC, Pinheiro LC.

Int Braz J Urol. 2015 Mar-Apr;41(2):353-9. doi: 10.1590/S1677-5538.IBJU.2015.02.24.


Prostate brachytherapy in New South Wales: patterns of care study and impact of caseload on treatment quality.

Thompson SR, Delaney GP, Gabriel GS, Izard MA, Hruby G, Jagavkar R, Bucci J, Barton MB.

J Contemp Brachytherapy. 2015 Jan;6(4):344-9. doi: 10.5114/jcb.2014.46610. Epub 2014 Nov 12.


Influence of zonal dosimetry on prostate brachytherapy outcomes.

Hong CW, Reddy CA, Wilkinson DA, Klein EA, Ciezki JP.

J Contemp Brachytherapy. 2015 Feb;7(1):17-22. doi: 10.5114/jcb.2015.48875. Epub 2015 Feb 4.


Comparison of three different techniques of low-dose-rate seed implantation for prostate cancer.

Ishiyama H, Satoh T, Sekiguchi A, Tabata K, Komori S, Tsumura H, Kawakami S, Soda I, Takenaka K, Iwamura M, Hayakawa K.

J Contemp Brachytherapy. 2015 Feb;7(1):3-9. doi: 10.5114/jcb.2015.48603. Epub 2015 Jan 26.


Relationship between two year PSA nadir and biochemical recurrence in prostate cancer patients treated with iodine-125 brachytherap.

Franca CA, Vieira SL, Carvalho AC, Bernabe AJ, Penna AB.

Radiol Bras. 2014 Mar-Apr;47(2):89-93. doi: 10.1590/S0100-39842014000200010.


Radiobiological effect induced by different activities of (125)I seed brachytherapy in a hepatocellular carcinoma model.

Qin QH, Huang BS, Tan QX, Yang WP, Lian B, Wei CY.

Int J Clin Exp Med. 2014 Dec 15;7(12):5260-7. eCollection 2014.


Pre-plan parameters predict post-implant D90 ≥ 140 Gy for (125)I permanent prostate implants.

Alexander J, Weinberg V, Gottschalk AR, Hsu IC, Shinohara K, Roach M 3rd.

J Contemp Brachytherapy. 2014 Jun;6(2):143-53. doi: 10.5114/jcb.2014.43248. Epub 2014 Jun 3.


Long-term outcome of early stage prostate cancer treated with brachytherapy analysis after a mean follow-up of 7 years.

Yan W, Chen J, Zhou Y, Zhou Z, Mai Z, Ji Z, Li H, Zhang F.

Springerplus. 2014 Jul 15;3:357. doi: 10.1186/2193-1801-3-357. eCollection 2014.


Bioevaluation of (125) I Ocu-Prosta seeds for application in prostate cancer brachytherapy.

Mukherjee A, Sarma HD, Saxena S, Kumar Y, Chaudhari P, Goda JS, Adurkar P, Dash A, Samuel G.

Indian J Med Res. 2014 Apr;139(4):555-60.


Recent developments and best practice in brachytherapy treatment planning.

Lee CD.

Br J Radiol. 2014 Sep;87(1041):20140146. doi: 10.1259/bjr.20140146. Epub 2014 Jun 2. Review.

Items per page

Supplemental Content

Support Center